MILPITAS, CA--(Marketwired - Nov 10, 2015) - FireEye, Inc. (NASDAQ: FEYE), the leader at stopping today's advanced cyber attacks, today announced participation in the Wells Fargo 2015 Technology, Media and Telecom Conference.
The company's presentation is scheduled for 1:25 pm EST Tuesday Nov. 10, 2015 and will be webcast. Links to the live and archived webcasts will be available from the investor relations section of the company's website.
The power of IMET as a combination drug makes these successes perhaps even more meaningful. They do not compete with IMET, but increase the possibilities. There are many partial solutions to the mystery of cancer, including understanding the properties of cancer stem cells and immortal cells.
FireEye has already lost more than 50% of its value. Catch a falling knife carefully, with the right kind of gloves. Mergers are coming.
Hologic Inc. HOLX reported fourth-quarter fiscal 2015 adjusted earnings per share (EPS) of 43 cents, up 13.2% year over year (excluding the one-time benefit of amending the company's license agreement with Roka Bioscience). Adjusted EPS also beat the Consensus Estimate by a penny and exceeded the company's guidance of 41–42 cents.
Notably, in the reported quarter, Hologic’s bottom line grew at a faster rate than revenues, owing to an improvement in gross and operating margins, which was however partially offset by currency and share account headwinds.
On a reported basis, the company recorded net income of $25.2 million or 9 cents per share, reflecting year-over-year decline of 10.6% or 10%, respectively.
Hologic’s fiscal 2015 adjusted EPS of $1.67 reflected a year-over-year improvement of 10.6%. The fiscal EPS figure also beat the Consensus Estimate by a penny and exceeded the company’s expectation of $1.65–$1.66 per share.
The market manipulators are being taken down and exposed. Imetelstat brings remissions, and chronic conditions for many, if not all blood cancers, and perhaps full cures in some cases. IMET is enhanced in combination with other medicines. The FDA endorses IMET (ODD status), and logic shouts for full, international approval. It's all coming together (perfect storm) for IMET, Janssen (JNJ) and Geron in the most positive way.
JNJ and Geron certainly have some "special agreements" that put JNJ in complete control of IMET. I would expect JNJ to tie up Geron as much as it is legally possible. Geron and IMET are totally dependent on JNJ and the 80 or so trial sites. "Chippy" is no fool, and knows the value of IMET, and the value of JNJ as a partner. You can argue that he does not deserve the 100's of millions that he is likely to pocket.